Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?

Opinión del Comité Consultivo de Inmunizaciones Sociedad Chilena de Infectología: Vacuna neumocóccica conjugada en niños y la emergencia de serotipo 19A

(2016) Marcela Potin et al.   Revista Chilena de Infectologia

Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil

(2016) Maria-Cristina de C. Brandileone et al.   VACCINE

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants

(2015) Alienke J. Wijmenga-Monsuur et al.   PLoS One

Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality

(2014) Zitta Barrella Harboe et al.   CLINICAL INFECTIOUS DISEASES

Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada

(2014) Philippe De Wals et al.   VACCINE

Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial

(2014) Miguel W. Tregnaghi et al.   PLOS MEDICINE

Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

(2014) Carla Magda Allan S Domingues et al.   Lancet Respiratory Medicine

Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010

(2012) Elizabeth Castañeda et al.   BMC INFECTIOUS DISEASES

Effects of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugate Vaccine on Nasopharyngeal Bacterial Colonization in Young Children: A Randomized Controlled Trial

(2012) M. R. van den Bergh et al.   CLINICAL INFECTIOUS DISEASES

Impact of 13-valent Pneumococcal Conjugate Vaccine on Pneumococcal Nasopharyngeal Carriage in Children With Acute Otitis Media

(2012) Robert Cohen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Pneumococcal disease: emergence of serotypes 19A and 7F following conjugate pneumococcal vaccination in a Mexican hospital

(2012) Enrique Chacon-Cruz et al.   Journal of Infection in Developing Countries

Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

(2010) William P Hausdorff et al.   BMC Pediatrics

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]

(2010) Sean T. Duggan   DRUGS

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

(2010) Dorothee M. Kieninger et al.   VACCINE

Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL